All In Biotech

Drug Trial Radar · NCT03228862

Optimal Doses of Ergocalciferol Supplementation for Treatment of Hypovitaminosis D in Adults

Optimal Initial and Maintenance Doses of Ergocalciferol Supplementation for Treatment of Hypovitaminosis D in Thai Adults: A Randomized, Double-blinded Dose-comparison Study

Last checked: Nov 20, 2026Latest source record: Jul 26, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

360

Actual

Start

May 1, 2017

Primary completion

Feb 1, 2018

Study completion Feb 1, 2018

Sponsor

Lead sponsor
Chulalongkorn UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 25, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To investigate the optimal initial and maintenance doses of vitamin D2 supplementation for the treatment of vitamin D insufficiency in Thai adults, and to determine the prevalence of and risk factors for hypovitaminosis D among Thai adults.

Conditions

  • Vitamin D2 Supplementation in Vitamin D Insufficiency

Interventions

  • ErgocalciferolDrug

    Ergocalciferol 40000, 60000 and 80000 once weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. serum 25OHD phase 1Time frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chulalongkorn Univerity and King Chulalongkorn Memorial Hospital

    Bangkok, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.